Institutional members access full text with Ovid®

Share this article on:

Initial Disease Course and Treatment in an Inflammatory Bowel Disease Inception Cohort in Europe: The ECCO-EpiCom Cohort

Burisch, Johan MD1; Pedersen, Natalia MD1; Cukovic-Cavka, Silvja MD2; Turk, Niksa MD2; Kaimakliotis, Ioannis MD3; Duricova, Dana PhD4; Shonová, Olga MD5; Vind, Ida PhD6; Avnstrøm, Søren DMSc6; Thorsgaard, Niels DMSc7; Krabbe, Susanne8; Andersen, Vibeke PhD8,9,10; Dahlerup Jens, Frederik DMSc11; Kjeldsen, Jens PhD12; Salupere, Riina MD13; Olsen, Jónger14ð; Nielsen, Kári Rubek MD14; Manninen, Pia MD15; Collin, Pekka MD15; Katsanos, Konstantinnos H. MD16; Tsianos, Epameinondas V. PhD16; Ladefoged, Karin DMSc17; Lakatos, Laszlo MD18; Bailey, Yvonne19; O’Morain, Colm MD19; Schwartz, Doron MD20; Odes, Selwyn MD20; Martinato, Matteo21,22; Lombardini, Silvia MD22,23; Jonaitis, Laimas MD24; Kupcinskas, Limas MD25; Turcan, Svetlana MD25; Barros, Louisa MD26; Magro, Fernando MD27,28,29; Lazar, Daniela MD30; Goldis, Adrian MD30; Nikulina, Inna MD31; Belousova, Elena MD31; Fernandez, Alberto MD32; Hernandez, Vicent MD33; Almer, Sven PhD34,35; Zhulina, Yaroslava MD36; Halfvarson, Jonas PhD36,37; Tsai, Her-Hsin MD38; Sebastian, Shaji MD38; Lakatos, Peter Laszlo PhD39; Langholz, Ebbe DMSc40; Munkholm, Pia DMSc1for the EpiCom Group

doi: 10.1097/01.MIB.0000436277.13917.c4
Original Clinical Articles

Background: The EpiCom cohort is a prospective, population-based, inception cohort of inflammatory bowel disease (IBD) patients from 31 European centers covering a background population of 10.1 million. The aim of this study was to assess the 1-year outcome in the EpiCom cohort.

Methods: Patients were followed-up every third month during the first 12 (±3) months, and clinical data, demographics, disease activity, medical therapy, surgery, cancers, and deaths were collected and entered in a Web-based database (

Results: In total, 1367 patients were included in the 1-year follow-up. In western Europe, 65 Crohn’s disease (CD) (16%), 20 ulcerative colitis (UC) (4%), and 4 IBD unclassified (4%) patients underwent surgery, and in eastern Europe, 12 CD (12%) and 2 UC (1%) patients underwent surgery. Eighty-one CD (20%), 80 UC (14%), and 13 (9%) IBD unclassified patients were hospitalized in western Europe compared with 17 CD (16%) and 12 UC (8%) patients in eastern Europe. The cumulative probability of receiving immunomodulators was 57% for CD in western (median time to treatment 2 months) and 44% (1 month) in eastern Europe, and 21% (5 months) and 5% (6 months) for biological therapy, respectively. For UC patients, the cumulative probability was 22% (4 months) and 15% (3 months) for immunomodulators and 6% (3 months) and 1% (12 months) for biological therapy, respectively in the western and eastern Europe.

Discussion: In this cohort, immunological therapy was initiated within the first months of disease. Surgery and hospitalization rates did not differ between patients from eastern and western Europe, although more western European patients received biological agents and were comparable to previous population-based inception cohorts.

Article first published online 21 November 2013Supplemental Digital Content is Available in the Text.

1Medical Section, Digestive Disease Centre, Medical Section, Herlev University Hospital, Copenhagen, Denmark;

2Division of Gastroenterology and Hepatology, University Hospital Center Zagreb, University of Zagreb School of Medicine, Zagreb, Croatia;

3Nicosia Private Practice, Nicosia, Cyprus;

4IBD Center ISCARE, Charles University, Prague, Czech Republic;

5Gastroenterology Department, Hospital České Budějovice, České Budějovice, Czech Republic;

6Department of Medicine, Amager Hospital, Amager, Denmark;

7Department of Medicine, Herning Central Hospital, Herning, Denmark;

8Medical Department, Viborg Regional Hospital, Viborg, Denmark;

9Medical Department, Hospital of Southern Jutland, Aabenraa, Denmark;

10Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark;

11Department of Medicine V (Hepatology and Gastroenterology), Aarhus University Hospital, Arhus, Denmark;

12Department of Medical Gastroenterology, Odense University Hospital, Odense, Denmark;

13Division of Endocrinology and Gastroenterology, Tartu University Hospital, Tartu, Estonia;

14Medical Department, The National Hospital of the Faroe Islands, Torshavn, Faroe Islands;

15Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere, Finland;

161st Division of Internal Medicine and Hepato-Gastroenterology Unit, University Hospital, Ioannina, Greece;

17Medical Department, Dronning Ingrids Hospital, Nuuk, Greenland;

18Department of Medicine, Csolnoky F. Province Hospital, Veszprem, Hungary;

19Department of Gastroenterology, Adelaide and Meath Hospital, Trinity College of Dublin, Dublin, Ireland;

20Department of Gastroenterology and Hepatology, Soroka Medical Center and Ben Gurion University of the Negev, Beer Sheva, Israel;

21U.O. Gastroenterologia, Azienda Ospedaliera, Università di Padova, Padova, Italy;

22EpiCom Northern Italy Centre based in Crema & Cremona, Padova and Reggio Emilia, Italy;

23UO Medicina 3° e Gastroenterologia, Azienda Ospedaliera Arcispedale S Maria Nuova, Reggio Emilia, Italy;

24Institute for Digestive Research, Lithuanian University of Health Sciences, Kaunas, Lithuania;

25Department of Gastroenterology, State University of Medicine and Pharmacy of the Republic of Moldova, Chisinau, Republic of Moldova;

26Department of Medicine, Hospital de Vale de Sousa, Porto, Portugal;

27Department of Gastroenterology, Hospital de São João, Porto, Portugal;

28Institute of Pharmacology and Therapeutics, Oporto Medical School, Porto, Portugal;

29Institute for molecular and cell biology, University of Porto, Porto, Portugal;

30Clinic of Gastroenterology, University of Medicine ‘Victor Babes’, Timisoara, Romania;

31Department of Gastroenterology, Moscow Regional Research Clinical Institute, Moscow, Russia;

32Gastroenterology Department, POVISA Hospital, Vigo, Spain;

33Gastroenterology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain;

34Division of Gastroenterology and Hepatology, Karolinska Instutue, Stockholm, Sweden;

35Department of Gastroenterology/UHL, County council of Östergötland, Linköping, Sweden;

36Department of Medicine, Division of Gastroenterology, Örebro University Hospital, Örebro, Sweden;

37School of Health and Medical Sciences, Örebro University, Örebro, Sweden;

38Hull and East Yorkshire NHS Trust & Hull and York Medical School, Hull Royal Infirmary, Kingston Upon Hull, United Kingdom;

391st Department of Medicine, Semmelweis University, Budapest, Hungary; and

40Department of Medical Gastroenterology, Gentofte Hospital, Copenhagen, Denmark.

Reprints: Johan Burisch, MD, Digestive Disease Centre, Medical Section, Herlev University Hospital, Herlev Ringvej 75, DK-2730, Denmark (e-mail:

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (

Supported by unrestricted grant from the Danish Colitis Crohn Patients Organization, the Vibeke Binder and Povl Riis’ Foundation, the Scientific Council at the Herlev Hospital, the Sigrid Rigmor Moran Foundation, the Aage and Johanne Louis-Hansens Foundation, the Munkholm Foundation, the C.C. Klestrup and Henriette Klestrup Foundation, the Knud and Dagny Gad Andresens Foundation, the Else and Mogens Wedell-Wedellsborgs Foundation, the Direktør Jacob Madsen and Olga Madsens Foundation, ScanVet, the Torben og Alice Frimodt Foundation, Lægernes forsikringsforening af 1891, the Bengt Ihres Foundation, the Nanna Svartz Foundation, the Örebro University Hospital Research Foundation, the Örebro County Research Foundation, The Swedish Foundation for Gastrointestinal Research, The Swedish Research Council, The Swedish Society of Medicine, the Research Council of South-East Sweden, the County Council of Östergötland, The Swedish Organization for the Study of Inflammatory Bowel Disease, the Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital, and the European Crohn’s and Colitis Organization.

The authors have no conflicts of interest to disclose.

Received September 04, 2013

Accepted September 24, 2013

© Crohn's & Colitis Foundation of America, Inc.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website